Cytochrome P450 17A1 (also known as CYP17A1 and cytochrome P450c17) catalyses the biosynthesis of androgens in humans 1 . As prostate cancer cells proliferate in response to androgen steroids 2,3 , CYP17A1 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic castration-resistant prostate cancer 4 , but drug development has been hampered by lack of information regarding the structure of CYP17A1. Here we report X-ray crystal structures of CYP17A1, which were obtained in the presence of either abiraterone, a first-in-class steroidal inhibitor recently approved by the US Food and Drug Administration for latestage prostate cancer 5 , or TOK-001, an inhibitor that is currently undergoing clinical trials 4,6 . Both of these inhibitors bind the haem iron, forming a 606 angle above the haem plane and packing against the central I helix with the 3b-OH interacting with aspargine 202 in the F helix. Notably, this binding mode differs substantially from those that are predicted by homology models and from steroids in other cytochrome P450 enzymes with known structures, and some features of this binding mode are more similar to steroid receptors. Whereas the overall structure of CYP17A1 provides a rationale for understanding many mutations that are found in patients with steroidogenic diseases, the active site reveals multiple steric and hydrogen bonding features that will facilitate a better understanding of the enzyme's dual hydroxylase and lyase catalytic capabilities and assist in rational drug design. Specifically, structure-based design is expected to aid development of inhibitors that bind only CYP17A1 and solely inhibit its androgen-generating lyase activity to improve treatment of prostate and other hormone-responsive cancers.
Cytochrome P450 17A1 (also known as CYP17A1 and cytochrome P450c17) catalyses the biosynthesis of androgens in humans 1 . As prostate cancer cells proliferate in response to androgen steroids 2,3 , CYP17A1 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic castration-resistant prostate cancer 4 , but drug development has been hampered by lack of information regarding the structure of CYP17A1. Here we report X-ray crystal structures of CYP17A1, which were obtained in the presence of either abiraterone, a first-in-class steroidal inhibitor recently approved by the US Food and Drug Administration for latestage prostate cancer 5 , or TOK-001, an inhibitor that is currently undergoing clinical trials 4, 6 . Both of these inhibitors bind the haem iron, forming a 606 angle above the haem plane and packing against the central I helix with the 3b-OH interacting with aspargine 202 in the F helix. Notably, this binding mode differs substantially from those that are predicted by homology models and from steroids in other cytochrome P450 enzymes with known structures, and some features of this binding mode are more similar to steroid receptors. Whereas the overall structure of CYP17A1 provides a rationale for understanding many mutations that are found in patients with steroidogenic diseases, the active site reveals multiple steric and hydrogen bonding features that will facilitate a better understanding of the enzyme's dual hydroxylase and lyase catalytic capabilities and assist in rational drug design. Specifically, structure-based design is expected to aid development of inhibitors that bind only CYP17A1 and solely inhibit its androgen-generating lyase activity to improve treatment of prostate and other hormone-responsive cancers.
CYP17A1 is a membrane-bound dual-function monooxygenase with a critical role in the synthesis of many human steroid hormones 1 . The 17a-hydroxylase activity of CYP17A1 is required for the generation of glucocorticoids such as cortisol, but both the hydroxylase and 17,20-lyase activities of CYP17A1 are required for the production of androgenic and oestrogenic sex steroids ( Supplementary Fig. 1 ). CYP17A1 is an important target for the treatment of breast and prostate cancers that proliferate in response to oestrogens and androgens 2,3 . In the absence of structural information, CYP17A1 inhibitors have been designed that are thought to bind the cytochrome P450 haem iron 4 , but it has been difficult to rationalize or predict other structural features that are critical for effective and selective CYP17A1 inhibition. In addition, structural information is important for understanding 17-hydroxylase deficiencies and may also improve our understanding of polycystic ovary disease 7 . We determined the structures of human CYP17A1 when bound to two clinically relevant CYP17A1 inhibitors ( Supplementary Fig. 2 ). Abiraterone is the active form of a prodrug that was recently approved by the US Food and Drug Administration for metastatic prostate cancer 5, 8 and is under investigation for breast cancer 9 . TOK-001 is currently undergoing clinical trials for prostate cancer 4 .
A truncated, His-tagged version of the human CYP17A1 protein was generated from a synthetic complementary DNA that was engineered to remove the single amino-terminal transmembrane helix, and this CYP17A1 was expressed in Escherichia coli. The resulting CYP17A1 was membrane bound and so it was solubilized with detergent before purification. This CYP17A1 binds abiraterone (17-(3-pyridyl)androsta-5,16-dien-3b-ol) ( Fig. 1a ) and TOK-001 (17-(1H-Benzimidazol-1yl)androsta-5,16-dien-3b-ol) with decreases in absorbance at 402 nm and increases in absorbance at 424 nm, consistent with nitrogen binding to the haem iron (type II interaction) with dissociation constant (K d ) values of ,100 nM ( Fig. 1a , inset). Similar titrations with the substrates progesterone ( Fig. 1b ) and pregnenolone revealed decreases in absorbance at 419 nm and increases in absorbance at 385 nm, which is indicative of the ligand displacing water from the haem (type I interaction). CYP17A1 binds pregnenolone (K d ,100 nM) more tightly than progesterone (K d 229 6 14 nM; Fig. 1b , inset). We found that full-length enzyme 10 had a similar k cat and three-fold higher Michaelis constant (k cat 1.31 6 0.03 min 21 , K m 11.4 6 0.7 mM) compared to the truncated form (k cat 1.31 6 0.03 min 21 , K m 3.7 6 0.3 mM). The half-maximum inhibitory concentration (IC 50 ) values for abiraterone (201 6 1 nM) were lower than for TOK-001 (503 6 1 nM) ( Fig. 1c ). Thus, truncated human CYP17A1 is a functional enzyme in terms of ligand binding, catalytic function and inhibition.
Both structures with abiraterone (2.6 Å ) and TOK-001 (2.4 Å ) demonstrate the characteristic cytochrome P450 fold ( Fig. 2a ) and have four very similar protein copies in each asymmetric unit ( Supplementary Table 1 ). Consistent with spectral binding data, abiraterone and TOK-001 bind with the nitrogen of the C17 pyridine or benzimidazole, respectively, forming a coordinate covalent bond with the haem iron ( Fig. 2b, d ). The steroidal cores of these inhibitors rise at an angle of 60u above the haem plane, directed between the F and G helices ( Fig. 2b, d) , and essentially overlap with each other (Fig. 2f ). The unsubstituted a-face packs flat against the I helix where G301, A302 and adjacent residues form a highly complementary hydrophobic planar surface (Fig. 2b) . The 3b-OH groups of abiraterone ( Fig. 2b ) and TOK-001 ( Fig. 2d ) hydrogen bond with N202 in the F helix (,2.6 Å and ,2.4 Å , respectively).
Although inhibitors occupy the majority of the enclosed active site, the void extends beyond these ligands in several directions. First, the active site wall nearest the inhibitor b-face is not as complementary to the steroid core as to the a-face. The C18 and C19 methyl groups project towards a crevice between the B9 helix, the b4 loop and the loop following the F helix ( Fig. 2b ). Only three side chains of the cavity wall come within 4 Å of C18 or C19. The cavity wall facing the b-face of abiraterone or TOK-001 is primarily lined with hydrophobic atoms of A105, S106, A113, F114, I206, L209, V236 and V482 ( Fig. 2c ), but there are two notable exceptions. R239 and D298 extend from the G and I helices, respectively, to orient their basic and acidic termini towards C6. These two polar side chains flank a substantial extension of the active site void adjacent to C6. Second, in the abiraterone structure there is unfilled space in the active site cavity adjacent to the pyridine ring bordered by V366, A367, I371 and V483 (Fig. 2c ), and this volume is occupied by benzimidazole in the TOK-001 structure ( Fig. 2e ). Last, the most substantial active site cavity extension is from the 3b-OH of the inhibitors over the top of helix I and along the underside of helices F and G. This cavity is mostly lined by hydrophobic residues (I198, L243 and F300), but its 'roof' is bordered by several polar F and G helix residues (Y201, N202 and R239; Fig. 2c ) that interact with, or are located near, water molecules in this region. The overall cavity containing TOK-001 is similar to that observed when abiraterone is bound, except that the available void volume over helix I is slightly smaller (Fig. 2e ).
The single direct hydrogen bond between inhibitors and the protein is part of a larger hydrogen bonding network. In the abiraterone complex this network involves N202, E305, several conserved water molecules, R239, the backbone carbonyl of G297 and, in some molecules, Y201 ( Fig. 3 ). Although Y201 is not within hydrogen bonding distance to these waters for molecules A and B, the side chain rotates slightly towards abiraterone in molecules C and D to interact with one or both of the water molecules. TOK-001 has a very similar hydrogen bonding network ( Supplementary Fig. 3 ). These interactions are strongly reminiscent of the interactions that are conserved in the androgen, oestrogen, glucocorticoid, mineralocorticoid and progesterone receptors 11 (Fig. 4a, b ). In each receptor, the 3b-OH or 3-keto group of steroids binds within a deep receptor pocket and forms hydrogen bonds with a glutamine or glutamate, an arginine and often a conserved water cavity (grey mesh). f, Abiraterone structure (yellow) superimposed on TOK-001 structure (purple) with respective voids (mesh). The B9 helix has been removed from panels c-f so that it is possible to view the ligands.
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molecule. These interactions are critical for ligand recognition by hormone receptors 12 and may also contribute to CYP17A1 selectivity for pregnenolone, progesterone and their 17a-hydroxy derivatives.
Notably, TOK-001 is both a CYP17A1 inhibitor and androgen receptor antagonist 13 , and the similarity of these binding modes is probably the reason for this dual mechanism of action.
Orientations of the native CYP17A1 substrates are of substantial value in understanding the function of this enzyme. Pregnenolone and progesterone were docked into the CYP17A1-abiraterone structure modelled as the Fe(IV)5O (compound I) catalytic state. Progesterone maintained the N202 hydrogen bond. The distances from C17 and C16 to the catalytic oxygen were 3.7 Å and 3.9 Å , respectively, distances that are consistent with the experimentally observed major 17a-OH and minor 16a-OH progesterone metabolites. The pregnenolone 3b-OH hydrogen was also bonded to N202 and the C17 atom was 3.6 Å from the Compound I oxygen ( Supplementary  Fig. 4 ). However, the active site topology may be altered in the presence of substrates and this is an important area for further investigation.
CYP17A1 can be compared to three other P450 enzymes that are involved in steroidogenesis or cholesterol metabolism with reported steroid complex structures: CYP19A1 (aromatase) 14 , CYP11A1 (cholesterol side-chain cleavage enzyme) 15 and CYP46A1, a cholesterol 24hydroxylase 16 . Although all four enzymes maintain the canonical cytochrome P450 fold, CYP19A1, CYP11A1 and CYP46A1 orient steroids in the opposite direction from CYP17A1 so that the steroid ligands are positioned over the K-L loop directed towards the b1 sheet (as shown for CYP11A1 in Fig. 4c ) instead of oriented towards helices F and G.
More than 50 CYP17A1 mutations have been identified, and most of these were identified in patients with 17-hydroxylase deficiencies. The biochemical effects of many clinical mutations can be rationalized by examining the CYP17A1 structure ( Supplementary Fig. 5 and Supplementary Table 2 ). Mutations R96W, R125Q, H373D/N and R440H/C all alter residues that directly interact with the haem propionates and probably disrupt haem binding, resulting in the complete loss of activity that was observed [17] [18] [19] [20] [21] [22] . Mutations E305G, R347H/ C, R358Q and R449A eliminate only the lyase activity of CYP17A1 [23] [24] [25] . E305 forms a hydrogen bond to N202 in the active site, indicating a role in substrate positioning, whereas the other residues are on the proximal face of the protein ( Supplementary Fig. 5 ), and this is consistent with their proposed role in cytochrome b 5 binding 23, 26 , which promotes lyase activity. Finally, reduction of the minor 16a-hydroxyprogesterone metabolite is reported for the artificial mutation A105L 27 , consistent with its location in the active site facing the b-face where the additional bulk may reduce the steroid movement within the active site.
Abiraterone and TOK-001 have several features that make them effective inhibitors of CYP17A1: first, a heterocyclic nitrogen that coordinates to the haem iron; second, a planar a-face to pack against the I helix; and third, hydrogen bonding interactions of 3b-OH with conserved polar residues in a hydrogen binding network. These structures provide a model for the binding of substrates and other inhibitors that is very different from binding orientations that have previously been proposed by homology modelling and docking studies and from structures that have been demonstrated in other steroid-metabolizing cytochrome P450 enzymes. Perhaps most importantly, the cavity that is observed is not bilobed as predicted by many modelling studies 28, 29 . CYP17A1 interactions with these inhibitors are instead more reminiscent of steroid binding to steroid receptors, and this may be the origin of the TOK-001 dual mechanism of action. Thus, these structures contribute to a better understanding of the function and inhibition of CYP17A1 in a way that should substantially benefit the apprehension of enzyme dysfunction in clinical disease and enable structure-based drug design of CYP17A1 inhibitors for treating hormone-responsive cancers, particularly prostate cancer.
METHODS SUMMARY
A synthetic cDNA for human CYP17A1 was modified to delete residues 2-19, substitute the hydrophilic sequence Arg 20-Arg 21-Cys 22-Pro 23 with Ala 20-Lys 21-Lys 22-Thr 23 and add a carboxy-terminal four-histidine tag ( Supplementary  Fig. 6 ) before cloning into the pCWori 1 plasmid and overexpression in Escherichia a, The hydrogen bonding network near the abiraterone 3b-OH involves N202, R239 and conserved waters. b, The androgen receptor (PDB 3L3X) has a similar hydrogen bond network with R752, Q711 and several waters that interact with the dihydrotestosterone ketone. c, The structure of CYP17A1with abiraterone (yellow) superimposed on the structure of CYP11A1 with 20,22-dihydroxycholesterol (PDB 3NA0, pink). This shows that there are markedly different steroid orientations between the two structures.
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coli JM109 cells. Protein was purified by nickel affinity, cation exchange and size exclusion chromatography. Abiraterone was synthesized (see Methods). Binding affinities were determined using an ultraviolet-visible spectral shift assay. Progesterone 17a-hydroxylation was evaluated using HPLC separation and ultraviolet detection. For crystallography, inhibitors were included throughout purification. Crystals were grown from CYP17A1 (30 mg ml 21 ) complexed with inhibitor using hanging-drop vapour diffusion to equilibrate against 30% PEG 3350, 0.175 M Tris, pH 8.5, 0.30 M ammonium sulphate and 3% glycerol. Diffraction data were collected and phased by molecular replacement. Iterative model building and refinement generated the final model. Substrates were docked using Surflex-Dock.
METHODS

Synthesis and characterization of abiraterone.
A stirred solution of 17iodoandrosta-5,16-dien-3b-ol (600 mg, 1.5 mmol) in tetrahydrofuran (20 ml) in a 100-ml round-bottomed flask was purged with argon. Bis(triphenylphosphine) palladium (II) chloride catalyst (11 mg, 0.016 mmol) and then diethyl(3-pyridyl) borane (265 mg, 1.8 mmol) were added. To the resultant orange solution, an aqueous solution of sodium carbonate (2 M, 5 ml) was added. The flask was fitted with a reflux condenser and the apparatus was purged again with argon. The mixture was then heated under reflux (at ,80 uC) and stirred for 4 days then allowed to cool. The mixture was poured into water and extracted with hot toluene (3 3 30 ml) . The toluene extracts were dried (using Na 2 CO 3 ) and concentrated. Column chromatography was performed with Et 2 O and toluene (with a ratio of 1:2) as the eluent to give abiraterone (350 mg, 66%) as a white crystalline solid: melting point 228-230 uC; IR O-H stretching frequency n max 3307 cm 21 ; 1 H NMR peak shifts in ppm (d) 1.07 (s, 3, H-19 36, 47.34, 42.32, 37.19, 36.71, 35.26, 31.81, 31.64, 30.45, 20.88, 19.35, 16.59 . The high resolution mass spectrum calculated the mass to charge ratio (m/z) C 24 Supplementary Fig. 6 ). N-terminal modifications were designed to increase solubility. This altered cDNA was inserted into the pCWori 1 expression vector and expressed in E. coli JM109 cells.
Cells were grown, collected and disrupted, as described previously 10, 30 . After centrifugation (5,000g), CYP17A1 was solubilized with either 4.8 mM Cymal-5 (for crystallography; Affymetrix) or 2% Emulgen 913 (for assays; Desert Biologicals) and then underwent ultracentrifugation (80,000g) for 60 min. The lysate was loaded onto a nickel nitriloacetic acid agarose (Qiagen) column and purified, as reported elsewhere 30 . Eluted CYP17A1 fractions were pooled, diluted fivefold with buffer A (50 mM Tris, pH 7.4, 20% glycerol, 100 mM glycine and 1 mM EDTA) and loaded on a HiTrap CM fast flow column (GE Healthcare). Protein was eluted in buffer A with 0.5 M NaCl, concentrated to ,1 ml, and loaded on a Superdex 200 16/60 size exclusion column (GE Healthcare). For crystallography, 10 mM abiraterone or TOK-001 (Shanghai Haoyuan Chemexpress) was added to all buffers. Protein crystallization, data collection and structure determination. CYP17A1 crystals were grown using hanging-drop vapour diffusion equilibration. CYP17A1 (30 mg ml 21 ) in buffer A supplemented with 10 mM abiraterone or TOK-001, 2.4 mM Cymal-5 and 0.5 M NaCl was equilibrated against 30% PEG 3350, 0.175 M Tris, pH 8.5, 0.30 M ammonium sulphate and 3% glycerol at 20 uC. Crystals were cryoprotected in 7:1 mother liquor:ethylene glycol and flash cooled in liquid nitrogen. Native data sets were collected at 0.98 Å , 100 K at the Stanford Synchrotron Radiation Laboratory beamline 9-2. Data were processed using Mosflm 31 and Scala 32 . The abiraterone complex was solved by molecular replacement using BALBES 33 with a final search model based on CYP2R1 (PDB 3CZH), and the TOK-001 structure was solved using Phaser 32 with the abiraterone structure as a search model. Model building and refinement were accomplished iteratively using COOT 34 and Refmac5 35 in CCP4 32 . Structure validation was performed using WHATCHECK 36 and PROCHECK 37 . Ramachandran plot analysis reveals per cent favourable/additional allowed/generously allowed/disallowed residues are 86.3/ 13.2/0.5/0.0 (abiraterone structure) and 86.2/13.3/0.5/0.0 (TOK-001 structure). X-ray statistics are provided ( Supplementary Table 1 ). Probe-occupied voids were calculated using VOIDOO 38 (probe radius 5 1.4 Å ; grid mesh 5 0.4 Å ). All figures were prepared using MacPyMOL 39 . Docking. The CYP17A1 active site was defined as described for other cytochromes P450 (ref. 40 ) with the addition of an oxygen molecule directly coordinated to the haem to mimic compound I of the cytochrome P450 catalytic cycle. Substrate coordinates were prepared and energy was minimized with SYBYL (Tripos International). Charges were assigned using the Gasteiger and Marsili method. Surflex-Dock 41 (Tripos International) was used to dock ligands as previously described 38 . The active site was a 10 Å sphere around the haem and pregnenolone. Movement of pregnenolone within the active site was not substantial, with the distances from C17 to O5Fe(IV) as 4.5 Å , from C16 to O5Fe(IV) as 4.5 Å , and from C21 to O5Fe(IV) as 3.0 Å for the lowest energy pose. Enzyme activity and IC 50 determinations. Progesterone 17a-hydroxylation was evaluated using a modified HPLC method with ultraviolet detection 42 . CYP17A1 (50 pmol) and rat NADPH-cytochrome P450 reductase 43 were mixed with a ratio of 1:4, incubated on ice (20 min) and added to buffer (50 mM Tris, pH 7.4 and 5 mM MgCl 2 ) containing progesterone (0-50 mM) to a total volume of 500 ml. Phosphatidylcholine (25 mg) was included for side-by-side kinetic comparisons with the full-length enzyme 10 . For IC 50 determinations, inhibitor concentrations were 0-1.5 mM for abiraterone and 0-3.0 mM for TOK-001. After warming (37 uC, 3 min), reactions were initiated by the addition of NADPH (20 ml 25 mM), incubated for 10 min (37 uC), quenched with 20% trichloroacetic acid (300 ml) and placed on ice. The 17a-hydroxyprogesterone metabolite was identified by ultraviolet detection at 248 nm after HPLC separation and co-eluted with authentic standards. The HPLC mobile phase was 40% acetonitrile, 60% water with 1% acetic acid and run at 1 ml min 21 (Luna (Phenomenex), 5 mm, C18, 50 3 4.6 mm). Ligand binding assays. Ligand binding assays were based on spectral differences that were detected after ligand titration and were performed as described 38 , except that the CYP17A1 concentration was 0.1 mM, the path length was 5 cm and the tight binding equation was used.
Functional data were analysed using Prism (GraphPad Software) and presented as mean 6 standard error.
